Treatment Response to Hydroxychloroquine, Lopinavir–Ritonavir, and Antibiotics for Moderate COVID-19: A First Report on the Pharmacological Outcomes from South Korea
Authors:
- Park Sung KyuPKPark Sung Kyu
- Min Ho AnMAMin Ho An
Preprint
Abstract
The authors have withdrawn this manuscript because of the controversy about hydroxychloroquine and potential changes in results after peer-review, the authors intend to share their results in formal publication. Therefore, the authors do not wish this work to be cited as reference for the project. If you have any questions, please contact the corresponding author.Keywords
This publication has 15 references indexed in Scilit:
- RETRACTED: Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trialInternational Journal of Antimicrobial Agents, 2020
- Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19New England Journal of Medicine, 2020
- Triple combination of interferon beta-1b, lopinavir–ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trialThe Lancet, 2020
- Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19)JAMA, 2020
- Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitroCell Discovery, 2020
- Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort studyThe Lancet, 2020
- A systematic review of lopinavir therapy for SARS coronavirus and MERS coronavirus—A possible reference for coronavirus disease‐19 treatment optionJournal of Medical Virology, 2020
- Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitroCell Research, 2020
- Value of intensive diagnostic microbiological investigation in low- and high-risk patients with community-acquired pneumoniaEuropean Journal of Clinical Microbiology & Infectious Diseases, 2005
- Contribution of a Urinary Antigen Assay (Binax NOW) to the Early Diagnosis of Pneumococcal PneumoniaClinical Infectious Diseases, 2004